[Experimental and clinical studies of the action of verapamil (finoptin) on the cerebral circulation in transient cerebral ischemia].

The experiments on unanesthetized rats have established that the intravenous injection of verapamil in a dose of 0.6 mg/kg during 30-minute carotid occlusion with subsequent recirculation prevents postischemic hypoperfusion, normalized oxidative processes and prevents brain tissue edema. In patients with transient cerebral circulatory disorders, a single injection of verapamil in a dose of 10 mg enhances the pulse filling of cerebral vessels.

[10-year experience with using Cavinton in cerebrovascular disorders].

Cavinton was used for 10 years in 967 patients with different cerebrovascular diseases. The highest effect was seen in patients with early forms and primarily chronic forms: vegetovascular (neurocirculatory) dystonia, initial manifestations of brain blood supply insufficiency, circulatory encephalopathy in the first and second stages. Improvement of the subjective status and a decrease of the intensity of vestibulocerebellar disorders were recorded by the end of the treatment in 75-85% of such patients.

[Calcium antagonists (finoptin and senzit) in the treatment of cerebrovascular disorders].

Finoptin and sensit produced a favourable effect in the treatment of 290 patients with initial manifestations of deficient blood supply to the brain, encephalopathy attended by circulatory disturbances and ischemic brain insult. Changes in the systemic and cerebral hemodynamics were more pronounced in middle-aged and elderly patients suffering from hypertension or its combination with atherosclerosis.

[Experience in the use of finoptin (verapamil) in cerebrovascular diseases].

Twenty-seven patients with dyscirculatory encephalopathies grades I and II and 20 acute ischemic stroke patients received finoptin (verapamil) at daily 5 to 10 mg i. v. or 120 to 240 mg oral doses.

[Effectiveness of using cavinton in patients of different ages with chronic forms of cerebrovascular diseases (clinico-rheographic research)].

A total of 171 patients of young, middle, and old age presenting initial manifestations of cerebral circulatory insufficiency and early disordered-circulatory encephalopathy were treated with cavinton. The clinical effect of the drug mostly expressed in a considerable decrease of subjective manifestations of the disease was fairly high in most patients of different age groups. The most pronounced positive shifts (according to REG) of the cerebral hemodynamics upon cavinton therapy were observed in young and middle-aged patients.

[Experimental and clinical research on the effect of senzit on the cerebral blood flow and hemostatic function in cerebral ischemia].

Senzit increased volume velocity of the cerebral blood flow and oxygen delivery to the brain tissues under normal conditions at the expense of a decrease of the cerebral vessels tone. In transient cerebral ischemia the drug prevents disorders of cerebral circulation and a lowering of oxygen tension in the brain tissue. A prophylactic administration of senzit in carotid arterial occlusion prevents the development of edema and death of animals.